Chairman and Director

Max Mawhinney was a co-founder and largest shareholder of Enterix Inc. in 1997 and is a co-founder and largest shareholder in Clinical Genomics Technologies. In addition to his experience in managing technology start-ups, Max was previously the founder and Managing Director of ICA Property, a company specialising in major industrial and commercial projects. ICA Property initiated a number of substantial development funds raising capital from major Australian institutional investors. Through ICA Property, Max was responsible for over $1billion in projects and has extensive experience in all aspects of business management and he has served on the Board of a number of Australian companies. Max was also a founding Director of the Property Industry Foundation, a charity set up to raise money to provide facilities for “kids on the streets” in Sydney. He was also a founding Director of the Urban Task Force, the major property industry lobby group. Max also has extensive farming interests.



Nicholas Conti is currently Vice President Licensing and Strategic Alliance for Quest Diagnostics. He has been involved with the development and licensing of technology for more than 20 years.

Dr. Conti previously held senior management roles in business development and R&D with Becton Dickinson, Union Carbide and Orchid Cellmark. Dr. Conti was the VP Corporate Development for Orchid Cellmark prior to joining Quest Diagnostics. Previous positions with Becton Dickinson include: VP Business Development Pre-Analytical Solutions Division, VP R&D and Business Operations BD and Director of Planning and Development Vacutainer™ Systems Division. Dr Conti started as a Senior Chemist with Union Carbide and became an R&D Program Coordinator and then a Licensing Manager for the Polyolefins Division.

Dr. Conti received a B.Sc. (Hons) from the University of Notre Dame, a Ph.D. in Chemistry from the University of Florida, and an MBA from the Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar. He is an Overseas Fellow of the Royal Society of Medicine as well as an Adjunct Professor at Seton Hall University in the Stillman School of Business, a Visiting Assistant Professor of Chemistry at Rutgers University, and a member of the Board of Directors of Hunterdon Hospice for Hunterdon Healthcare Systems. He is the Head Coach of the Northern Valley junior football team where he coaches as a volunteer.



Roy Davis joined the Clinical Genomics Board in 2018 to support CG’s exciting growth opportunities in liquid biopsy and cancer testing. Mr. Davis spent 27 years with Johnson & Johnson and held positions of increasing responsibility including Group President, Company Group Chairman, Worldwide Franchise Chairman, and President of J & J Development Corporation. He also served as Managing Director and General Manager for Ortho Diagnostics in Europe, Japan and the Americas and was the founding President of Veridex (a Johnson & Johnson Company), one of the first organizations to introduce breakthrough technology in the field of circulating tumor cells. He is currently a Senior Advisor for Huron Global Management Consulting and its Innosight subsidiary and was previously an Innovations Advisory Board Member for the Cleveland Clinic. Mr. Davis received a Bachelor of Science from the University of Albany, SUNY and a Master of Science from Rensselaer Polytechnic Institute.



An experienced Board director, Peter Jollie holds numerous Board positions including Deputy Chairman NAFDA, Director Murdoch Books and Syndicate Chairman CEO Institute. Previously Chairman of Downer EDI Limited; a Director of; Governor of the Heart Research Institute; Chairman of the Defense Housing Authority; and Director, Medical Research & Compensation Foundation.

Mr. Jollie has also held CEO positions, firstly as managing partner in the Ghana office of what is now KPMG, then as CEO in Australia and New Zealand for P&O Containers. He was Chairman of the New South Wales branch of the Institute of Chartered Accountants in Australia and President of the ICAA nationally.

Mr. Jollie has extensive financial skills derived from his time as a partner in KPMG (then Peat Marwick), CFO in Australia for parts of the Hawker de Havilland group, and CFO for Overseas Containers. He project managed the CTAL container terminal finance, construction and transfer of operations from White Bay. He was also a member of the Finance Commission for the Sydney 2000 Olympics bid.



Paul Kelly, MD, FRACP, is a founding partner of One Ventures, a Sydney based venture capital firm providing human and investment capital into high growth companies based on transformative technologies. For more than two decades, Paul has assisted and led early-stage and mid-stage companies to transform ideas, technologies and products into sustainable successful businesses. From 2003-2006 he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), a leading provider of genetic testing services where he developed and managed major operational and strategic restructuring. He was CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company that he co-founded in 1995 to discover and commercialize novel gene-based targets. He positioned Gemini for one of the UK’s largest biotechnology IPOs in 2000, completed strategic acquisitions in Europe and North America and ultimately oversaw the company’s successful merger with Sequenom (Nasdq:SQNM) valuing Gemini at over $250M in 2001.

Before becoming a biotechnology executive, Dr. Kelly had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent’s Hospital, Sydney, Australia. While serving as a Research Physician at the Garvan Institute for Medical Research in Sydney, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of Charmhealth and FindMe technologies, and is a nonexecutive director of Agamatrix Inc., a US-based medical device company he co-founded. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Dr. Kelly is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honors), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians.


Chief Executive Officer, Managing Director

Dr. Lawrence LaPointe is a co-founder and CEO of Clinical Genomics. Prior to launching the Company, Dr. LaPointe co-founded Enterix Inc. in 1997 and served as a member of its executive team until that Company was sold in 2006. As General Manager from start-up until 2000, he introduced the world’s first dedicated colorectal cancer screening service using a novel kit.

Dr. LaPointe has also served as Lab Manager of the Centre for Molecular Imaging Research at Massachusetts General Hospital (Harvard Medical School). Dr. LaPointe holds a Ph.D. in Bioinformatics (Flinders University, Australia) and a B.Sc. in Biological Sciences (Florida State University, USA). He holds multiple patents and has authored numerous scientific articles, conference presentations and invited talks.


Alternate Director

Richard Sands, a co-founder of Clinical Genomics, joined the management team in 2012 to oversee the company’s financial affairs. Mr. Sands is a Fellow of the Institute of Chartered Accountants in Australia and a Member of Chartered Secretaries Australia. Initially a Chartered Accountant with Wayland and Wayland, Mr. Sands subsequently held the position of Company Secretary and Corporate Lending Manager with Lloyds Bank Plc’s Australian subsidiary Lloyds International Limited. For the past two decades Mr. Sands has been a Principal at Karridale Pty Limited a corporate advisory firm. He holds a Bachelor of Commerce from the University of New South Wales (Australia).